The global hormone replacement therapy market size accounted for USD 37.40 billion in 2024, grew to USD 39.64 billion in 2025 and is predicted to surpass around USD 66.98 billion by 2034, representing a healthy CAGR of 6% between 2025 and 2034. The North America hormone replacement therapy market size is calculated at USD 16.25 billion in 2024 and is expected to grow at a fastest CAGR of 6.13% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Hormone Replacement Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Hormone Replacement Therapy Market, by Product, 2025-2034
8.1.1. Oestrogen Hormone Replacement Therapy
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Human Growth Hormone Replacement Therapy
8.1.2.1. Market Revenue and Forecast (2022-2034)
8.1.3. Thyroid Hormone Replacement Therapy
8.1.3.1. Market Revenue and Forecast (2022-2034)
8.1.4. Testosterone Hormone Replacement Therapy
8.1.4.1. Market Revenue and Forecast (2022-2034)
9.1. Hormone Replacement Therapy Market, by Route of Administration e, 2025-2034
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2022-2034)
9.1.2. Parenteral
9.1.2.1. Market Revenue and Forecast (2022-2034)
9.1.3. Transdermal
9.1.3.1. Market Revenue and Forecast (2022-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2022-2034)
10.1. Hormone Replacement Therapy Market, by Indication, 2025-2034
10.1.1. Menopause
10.1.1.1. Market Revenue and Forecast (2022-2034)
10.1.2. Hypothyroidism
10.1.2.1. Market Revenue and Forecast (2022-2034)
10.1.3. Male Hypogonadism
10.1.3.1. Market Revenue and Forecast (2022-2034)
10.1.4. Growth Hormone Deficiency
10.1.4.1. Market Revenue and Forecast (2022-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2022-2034)
11.1. Hormone Replacement Therapy Market, by Distribution Channel, 2025-2034
11.1.1. Hospitals Pharmacies
11.1.1.1. Market Revenue and Forecast (2022-2034)
11.1.2. Retail Pharmacies & Stores
11.1.2.1. Market Revenue and Forecast (2022-2034)
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast (2022-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2022-2034)
12.1.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.1.3. Market Revenue and Forecast, by Indication (2022-2034)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2022-2034)
12.1.5.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.1.5.3. Market Revenue and Forecast, by Indication (2022-2034)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2022-2034)
12.1.6.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.1.6.3. Market Revenue and Forecast, by Indication (2022-2034)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2022-2034)
12.2.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.2.3. Market Revenue and Forecast, by Indication (2022-2034)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2022-2034)
12.2.5.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.2.5.3. Market Revenue and Forecast, by Indication (2022-2034)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2022-2034)
12.2.6.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.2.6.3. Market Revenue and Forecast, by Indication (2022-2034)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2022-2034)
12.2.7.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.2.7.3. Market Revenue and Forecast, by Indication (2022-2034)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2022-2034)
12.2.8.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.2.8.3. Market Revenue and Forecast, by Indication (2022-2034)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2022-2034)
12.3.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.3.3. Market Revenue and Forecast, by Indication (2022-2034)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2022-2034)
12.3.5.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.3.5.3. Market Revenue and Forecast, by Indication (2022-2034)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2022-2034)
12.3.6.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.3.6.3. Market Revenue and Forecast, by Indication (2022-2034)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2022-2034)
12.3.7.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.3.7.3. Market Revenue and Forecast, by Indication (2022-2034)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2022-2034)
12.3.8.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.3.8.3. Market Revenue and Forecast, by Indication (2022-2034)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2022-2034)
12.4.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.4.3. Market Revenue and Forecast, by Indication (2022-2034)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2022-2034)
12.4.5.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.4.5.3. Market Revenue and Forecast, by Indication (2022-2034)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2022-2034)
12.4.6.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.4.6.3. Market Revenue and Forecast, by Indication (2022-2034)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2022-2034)
12.4.7.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.4.7.3. Market Revenue and Forecast, by Indication (2022-2034)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2022-2034)
12.4.8.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.4.8.3. Market Revenue and Forecast, by Indication (2022-2034)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2022-2034)
12.5.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.5.3. Market Revenue and Forecast, by Indication (2022-2034)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2022-2034)
12.5.5.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.5.5.3. Market Revenue and Forecast, by Indication (2022-2034)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2022-2034)
12.5.6.2. Market Revenue and Forecast, by Route of Administration (2022-2034)
12.5.6.3. Market Revenue and Forecast, by Indication (2022-2034)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2022-2034)
13.1. Novo Nordisk A/S
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Pfizer Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Endo International Plc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Allergen Plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Janssen NV
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Novartis AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Bayer AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck KGaA
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Mithra Pharmaceuticals
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Teva Pharmaceuticals
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample